GlassScriptPhysician profile
Clyde C Mendonca
NPI 1710919246
$5,202.01
in general payments reported to CMS, 2019-2025
35 companies · $1,826 in 2025
The $1,826 reported for 2025 was more than what 88% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $389 · 2020: $245 · 2021: $427 · 2022: $437 · 2023: $686 · 2024: $1,193 · 2025: $1,826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,513 · Education: $192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,512.87 |
| Education | $191.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $616.84 | 2019-2025 | Tavneos, Krystexxa, Aranesp |
| Astrazeneca Pharmaceuticals LP | $601.04 | 2019-2025 | Farxiga, Lokelma |
| Travere Therapeutics, INC. | $462.31 | 2022-2025 | Filspari |
| Otsuka America Pharmaceutical, INC. | $405.61 | 2019-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $361.38 | 2022-2025 | |
| Ardelyx, INC. | $298.11 | 2023-2025 | Ibsrela |
| Akebia Therapeutics INC | $217.24 | 2021-2025 | Vafseo, Auryxia |
| Glaxosmithkline, LLC. | $203.55 | 2020-2025 | Benlysta |
| Nxstage Medical, INC. | $185.89 | 2022-2025 | Nxstage System One |
| Mallinckrodt Hospital Products INC. | $174.40 | 2020-2025 | Acthar |
| Aurinia Pharma U.S., INC. | $169.26 | 2021-2025 | Lupkynis |
| Opko Pharmaceuticals, LLC | $154.40 | 2021-2025 | Rayaldee |
| Horizon Therapeutics Plc | $127.47 | 2021-2023 | Krystexxa |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $125.26 | 2024-2025 | Voyxact, Jynarque |
| Novartis Pharmaceuticals Corporation | $121.07 | 2024-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $119.43 | 2022-2025 | Injectafer |
| Vantive US Healthcare LLC | $104.90 | 2025 | |
| Vifor Pharma, INC. | $104.53 | 2020-2023 | Veltassa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.49 | 2023-2025 | Jardiance |
| Lilly USA, LLC | $77.10 | 2025 | Jardiance |
| Ani Pharmaceuticals, INC. | $77.05 | 2022-2023 | Purified Cortrophin Gel |
| Calliditas Therapeutics US INC. | $67.55 | 2023-2025 | Tarpeyo |
| Novo Nordisk INC | $46.07 | 2025 | Wegovy, Ozempic |
| Takeda Pharmaceuticals U.S.A., INC. | $36.31 | 2021-2022 | |
| Outset Medical INC | $32.97 | 2023 | |
| Alnylam Pharmaceuticals INC. | $29.95 | 2025 | Givlaari |
| Abbott Laboratories | $24.82 | 2023 | Cardiomems |
| Renalytix Ai, INC. | $23.96 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Ultragenyx Pharmaceutical INC. | $23.18 | 2025 | Crysvita |
| Alexion Pharmaceuticals, INC. | $21.55 | 2024 | Ultomiris |
| Kyowa Kirin, INC. | $21.18 | 2024 | Crysvita |
| Apellis Pharmaceuticals, INC. | $20.33 | 2025 | |
| Mallinckrodt Enterprises LLC | $19.48 | 2019 | |
| Corcept Therapeutics | $17.80 | 2025 | Korlym |
| Gilead Sciences, INC. | $10.53 | 2023 | Veklury |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clyde Mendonca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.